Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest macular hole Stories

2011-12-23 00:30:00

LEUVEN, Belgium, December 23, 2011 /PRNewswire/ -- If approved, ocriplasmin will be the first pharmacological treatment for symptomatic vitreomacular adhesion (VMA) including macular hole ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA)...

2011-10-20 11:10:00

LEUVEN, Belgium, October 20, 2011 /PRNewswire/ -- Leading retinal specialist also invited to present ocriplasmin responder analysis for the treatment of macular holes at Best of the Posterior Segment Specialty Meetings ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that three leading retinal specialists will present the responder analysis on...

2011-04-13 05:30:00

RICHMOND, Va., April 13, 2011 /PRNewswire/ -- Richmond surgeon, Dr. Stewart O'Keefe, was recently elected as president of the Central Virginia Juvenile Diabetes Research Foundation's Board of Directors. As a Retina Surgeon at Retina Institute of Virginia (RIV) and Stony Point Surgery Center, Dr. O'Keefe performs over 500 surgeries each year, many for complications of diabetes such as diabetic macular edema. The Juvenile Diabetes Research Foundation (JDRF) has over 100 chapters worldwide,...

2010-09-01 00:29:00

LEUVEN, Belgium, September 1, 2010 /PRNewswire-FirstCall/ -- - Data Presented at ASRS Confirm Previous Phase III Findings and Microplasmin's Potential to Transform the Treatment of Retinal Disorders ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of...

2010-06-07 00:28:00

LEUVEN, Belgium, June 7, 2010 /PRNewswire-FirstCall/ -- - Data Presented Show Microplasmin Cures Approximately 50% of Patients With Macular Hole ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that further data from the first successful Phase III trial with microplasmin (TG-MV-006) for the non-surgical treatment of vitreomacular adhesion (VMA) were presented at the...

2010-02-09 00:30:00

LEUVEN, Belgium, February 9 /PRNewswire-FirstCall/ -- - Paper Examines the Potential of Microplasmin to Improve the Treatment of a Range of Back of the Eye Diseases ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who...